1887

Abstract

Summary

Experimental induction of malignant lymphomas can be achieved in the cottontop tamarin by inoculation with Epstein-Barr (EB) virus. This system provides an animal model for assessing the efficacy of vaccine protection against the virus which is intended to reduce the incidence of human tumours associated with EB virus infection, namely endemic Burkitt’s lymphoma and undifferentiated nasopharyngeal carcinoma. Cottontop tamarins have been vaccinated with the major envelope glycoprotein of EB virus, gp340, incorporated into immune-stimulating complexes (iscoms) and were thereby protected against a 100% lymphomagenic dose of virus. The gp340 iscoms are highly immunogenic, requiring only a few micrograms of immunogen to induce protective immunity and thus would be a strong candidate for further development as an EB virus vaccine for use in man.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-69-8-2093
1988-08-01
2024-05-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/69/8/JV0690082093.html?itemId=/content/journal/jgv/10.1099/0022-1317-69-8-2093&mimeType=html&fmt=ahah

References

  1. BURKITT D. 1963 A lymphoma syndrome in tropical Africa. International Review of Experimental Pathology 267–138 Edited by Richter G. W., Epstein M. A. New York & London: Academic Press;
    [Google Scholar]
  2. CLEARY M. L., EPSTEIN M. A., FINERTY S., DORFMAN R. F., BORNKAMM G. W., KIRKWOOD J. K., MORGAN A. J., SKLAR J. 1985; Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228:722–724
    [Google Scholar]
  3. DALSGAARD K. 1978; A study of the isolation and characterisation of the saponin Quil A. Evaluation of its adjuvant activity with special reference to the application in the vaccination of cattle against foot-and-mouth disease. Acta veterinaria scandinavica supplement 69:1
    [Google Scholar]
  4. DAVID E. M., MORGAN A. J. 1988; Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography. Journal of Immunological Methods 108:231–236
    [Google Scholar]
  5. DE SCHRYVER A., KLEIN G., HENLE W., HENLE G. 1974; EB virus-associated antibodies in Caucasian patients with carcinoma of the nasopharynx and in long-term survivors after treatment. International Journal of Cancer 13:319–325
    [Google Scholar]
  6. DORFMAN R. F., BURKE I. S., BERARD C. 1982 A working formulation of non-Hodgkins lymphomas: background recommendations, histological criteria, and relationship to other classifications. Malignant Lymphomas351–368 Edited by Rosenberg S., Kaplan H. New York & London: Academic Press;
    [Google Scholar]
  7. EPSTEIN M. A. 1976; Epstein-Barr virus — is it time to develop a vaccine program?. Journalofthe National Cancer Institute 56:697–700
    [Google Scholar]
  8. EPSTEIN M. A., MORGAN A. J. 1987 Progress with subunit vaccines against the virus. The Epstein-Barr Virus: Recent Advances271–289 Edited by Epstein M. A., Achong B. G. London: Heinemann;
    [Google Scholar]
  9. EPSTEIN M. A., MORGAN A. J., FINERTY S., RANDLE B. J., KIRKWOOD J. K. 1985; Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, London 318:287–289
    [Google Scholar]
  10. FINERTY S., SCULLION F. T., MORGAN A. J. 1988; Demonstration in vitro of cell mediated immunity to Epstein-Barr virus in cottontop tamarins. Clinical and Experimental Immunology in press
    [Google Scholar]
  11. FRIZZERA G., HANTO D. W., GAJL-PECZALSKA J., ROSAI J., MCKENNA R. W., SIBLEY R. K., HOLAHAN K. P., LINDQUIST L. L. 1981; Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Research 41:4262–4279
    [Google Scholar]
  12. HENLE G., HENLE W. 1966; Immunofluorescence in cells derived from Burkitt’s lymphoma. Journal of Bacteriology 91:1248–1256
    [Google Scholar]
  13. HOWARD C. R., SUNDQUIST B., ALLAN J., BROWN S. E., CHEN S.-H., MOREIN B. 1987; Preparation and properties of immune-stimulating complexes containing hepatitis B virus surface antigen. Journal of General Virology 68:2281–2289
    [Google Scholar]
  14. LOVGREN K., LINDMARK J., PIPKORN R., MOREIN B. 1987; Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier. Journal of Immunological Methods 98:329–356
    [Google Scholar]
  15. MILLER G., SHOPE T., LISCO H., STITT D., LIPMAN M. 1972; Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leucocytes. Proceedings of the National Academy of Sciences, U.S.A 69:383–387
    [Google Scholar]
  16. MOREIN B., LOVGREN K., HOGLAND S., SUNDQUIST B. 1987; The iscom: an immunostimulating complex. Immunology Today 8:333–338
    [Google Scholar]
  17. MORGAN A. J., MACKETT M., FINERTY S., ARRAND J., EPSTEIN M. A. 1988; Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. Journal of Medical Virology in press
    [Google Scholar]
  18. OSTERHAUS A., WEDER K., UYTDEHAAG F., JARRET O., SUNDQUIST B., MOREIN B. 1985; Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. Journal of immunology 135:591–596
    [Google Scholar]
  19. RANDLE B., EPSTEIN M. A. 1984; A highly sensitive enzyme-linked immunosorbant assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340. Journal of Virological Methods 9:201–208
    [Google Scholar]
  20. SHANMUGARATNAM K. 1971 Studies on the etiology of nasopharyngeal carcinoma. International Review of Experimental Pathology 10361–413 Edited by Richter G. W., Epstein M. A. New York & London: Academic Press;
    [Google Scholar]
  21. SPELTERS G., DANSE L., BEUVERY E., STRIK I., VOS I. 1988; Local reactions of the saponin Quil A and a Quil A-containing iscom measles vaccine after intramuscular injection of rats: a comparison with the effects of DPT-polio vaccine. Fundamental and Applied Toxicology 10:425–430
    [Google Scholar]
  22. SUNDQUIST B., LOVGREN K., HOGLUND S., MOREIN B. 1988; Influenza virus iscoms: biochemical characterisation. Vaccine 6:44–48
    [Google Scholar]
  23. WAHREN B., NORDLUND S., AKESSON A., SUNDQUIST V.-A., MOREIN B. 1987; Monocyte and iscom enhancement of cell-mediated response to cytomegalovirus. Medical Microbiology and Immunology 176:13–19
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-69-8-2093
Loading
/content/journal/jgv/10.1099/0022-1317-69-8-2093
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error